 |
|
The clinical management of hepatocellular carcinoma in China: Progress and challenges
Shan Shan, Jidong Jia
Clin Mol Hepatol. 2023;29(2):339-341. Published online 2023 Mar 16 DOI: https://doi.org/10.3350/cmh.2023.0077
|
|
Citations to this article as recorded by
 How Possible Is the Elimination of Viral Hepatitis? An Analysis Based on the Global Burden of Disease from Hepatitis B and C, 1990–2019
Nelson Alvis-Guzman, Nelson J. Alvis-Zakzuk, Fernando De la Hoz Restrepo
Microorganisms.2024; 12(2): 388. CrossRef β-Sitosterol alleviates the malignant phenotype of hepatocellular carcinoma cells via inhibiting GSK3B expression
Ruoyu Wang, Dan Tang, Longyun Ou, Jiacheng Jiang, Yu-nan Wu, Xuefei Tian
Human Cell.2024; 37(4): 1156. CrossRef A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the ‘atezolizumab plus bevacizumab’ regimen
Yawen Xie, Yanxia Huang, Shuyue Liu
Nursing in Critical Care.2024;[Epub] CrossRef Biological impact and therapeutic implication of tumor-associated macrophages in hepatocellular carcinoma
Deming Li, Ting Zhang, Ye Guo, Cong Bi, Ming Liu, Gang Wang
Cell Death & Disease.2024;[Epub] CrossRef Tumor burden score and alpha-fetoprotein level predict prognosis of patients with unresectable hepatocellular carcinoma treated with tyrosine kinase inhibitor and anti-PD-1 antibody
Shichuan Tang, Tingfeng Huang, Cong Luo, Jun Fu, Kailing Zhang, Qingjing Chen, Jie Kong, Jianxi Zhang, Zhenghong Sun, Yongkang Diao, Kongying Lin, Yongyi Zeng
iLIVER.2024; 3(3): 100109. CrossRef
|